MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-31-2025
Merus N.V. Total Liabilities 2011-2025 | MRUS
Annual Total Liabilities Merus N.V.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 135 M | 99.2 M | 129 M | 140 M | 129 M | 132 M | 145 M | 179 M | 40.3 M | 7.86 M | 8.63 M | 6.58 M | 3.32 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 179 M | 3.32 M | 88.8 M |
Quarterly Total Liabilities Merus N.V.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 129 M | 138 M | 135 M | 135 M | 141 M | 145 M | 149 M | 99.2 M | 98.8 M | 106 M | 121 M | 129 M | 116 M | 118 M | 120 M | 140 M | 150 M | 160 M | 161 M | 129 M | 129 M | 129 M | 129 M | 132 M | 132 M | 132 M | 132 M | 147 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 161 M | 98.8 M | 132 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
38.4 M | $ 4.9 | 4.03 % | $ 813 M |  Canada |
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Aclaris Therapeutics
ACRS
|
64.8 M | $ 3.21 | -1.38 % | $ 248 M |  USA |
 |
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | USA |
 |
Aptevo Therapeutics
APVO
|
10.8 M | $ 1.06 | -6.22 % | $ 293 K | USA |
 |
Catalyst Biosciences
CBIO
|
38.1 M | $ 13.33 | -5.39 % | $ 878 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Ascendis Pharma A/S
ASND
|
1.29 B | $ 214.55 | -2.66 % | $ 5 B |  Danmark |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alterity Therapeutics Limited
ATHE
|
5.89 M | $ 3.1 | -5.93 % | $ 7.46 B |  Australia |
 |
Celldex Therapeutics
CLDX
|
45.3 M | $ 27.09 | -1.53 % | $ 1.74 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
161 M | $ 88.51 | 0.59 % | $ 9.14 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
124 M | $ 24.35 | 3.07 % | $ 2.88 B | USA |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
CureVac N.V.
CVAC
|
470 M | $ 5.02 | -0.59 % | $ 934 M | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
BioVie
BIVI
|
2.55 M | $ 1.43 | -1.72 % | $ 2.11 M | USA |
 |
ARCA biopharma
ABIO
|
13.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
5.38 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
243 M | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
3.12 B | $ 93.99 | -0.86 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
90.7 M | - | - | $ 1.01 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
389 M | $ 10.88 | 0.74 % | $ 1.41 B | USA |
 |
Albireo Pharma
ALBO
|
126 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
107 M | - | - | $ 2.17 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
845 M | $ 26.44 | 4.63 % | $ 1.28 B | USA |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
42.3 M | $ 9.6 | 0.42 % | $ 141 M | USA |
 |
Eton Pharmaceuticals
ETON
|
16.3 M | $ 15.97 | -4.37 % | $ 410 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 0.26 | -6.9 % | $ 566 M |  Israel |
 |
Evogene Ltd.
EVGN
|
15 M | $ 1.04 | -3.7 % | $ 27.9 M | Israel |
 |
Exelixis
EXEL
|
703 M | $ 41.27 | 0.95 % | $ 12 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
110 M | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
28.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M | USA |
 |
Avenue Therapeutics
ATXI
|
816 K | - | -52.27 % | $ 4.45 M | USA |
|
Foghorn Therapeutics
FHTX
|
330 M | $ 4.39 | -1.13 % | $ 241 M | USA |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
2.15 B | $ 551.37 | -2.29 % | $ 41.8 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
93.3 M | $ 2.35 | 2.17 % | $ 14.8 M | USA |
 |
AstraZeneca PLC
AZN
|
63.2 B | $ 91.19 | 1.51 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
6.5 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
1.45 B | $ 8.88 | -1.33 % | $ 1.45 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
2.59 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
1.76 B | $ 11.25 | -2.43 % | $ 728 M | USA |
 |
Biogen
BIIB
|
11.3 B | $ 174.69 | 0.34 % | $ 25.4 B | USA |